Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
复制标题
DOI:
10.1016/j.ccr.2012.11.017
复制
发表时间:
2013-01-14
期刊:
影响因子:
50.3
通讯作者:
Rudin CM
中科院分区:
文献类型:
--
作者:
Kim J;Aftab BT;Tang JY;Kim D;Lee AH;Rezaee M;Kim J;Chen B;King EM;Borodovsky A;Riggins GJ;Epstein EH Jr;Beachy PA;Rudin CM
Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer resistance to these inhibitors. We report here that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMOD477G medulloblastoma.
登录
查看更多内容
影响因子:
4
作者:
Chong, Curtis R.;Xu, Jing;Liu, Jun O.
通讯作者:
Liu, Jun O.
影响因子:
56.9
作者:
Berman, DM;Karhadkar, SS;Beachy, PA
通讯作者:
Beachy, PA
DOI:
10.1139/o66-100
发表时间:
1966-01-01
期刊:
CANADIAN JOURNAL OF BIOCHEMISTRY
影响因子:
--
作者:
KEELER, RF;BINNS, W
通讯作者:
BINNS, W
DOI:
10.1038/nrc2503
发表时间:
2008-10
期刊:
Nature reviews. Cancer
影响因子:
--
作者:
通讯作者:
--
影响因子:
64.8
作者:
Corbit, KC;Aanstad, P;Reiter, JF
通讯作者:
Reiter, JF